特里夫
先天免疫系统
生物
肺炎克雷伯菌
微生物学
免疫
细胞生物学
炎症体
炎症
效应器
免疫系统
Toll样受体
免疫学
大肠杆菌
基因
遗传学
作者
Cláudia Feriotti,Joana Sá‐Pessoa,Ricardo Calderón-González,Lili Gu,Brenda Morris,Ryoichi Sugisawa,José Luis Insua,Michael Carty,Amy Dumigan,Rebecca J. Ingram,Adrien Kissenpfening,Andrew Bowie,José A. Bengoechea
出处
期刊:Cell Reports
[Cell Press]
日期:2022-08-01
卷期号:40 (6): 111167-111167
被引量:33
标识
DOI:10.1016/j.celrep.2022.111167
摘要
Many bacterial pathogens antagonize host defense responses by translocating effector proteins into cells. It remains an open question how those pathogens not encoding effectors counteract anti-bacterial immunity. Here, we show that Klebsiella pneumoniae exploits the evolutionary conserved innate protein SARM1 to regulate negatively MyD88- and TRIF-governed inflammation, and the activation of the MAP kinases ERK and JNK. SARM1 is required for Klebsiella induction of interleukin-10 (IL-10) by fine-tuning the p38-type I interferon (IFN) axis. SARM1 inhibits the activation of Klebsiella-induced absent in melanoma 2 inflammasome to limit IL-1β production, suppressing further inflammation. Klebsiella exploits type I IFNs to induce SARM1 in a capsule and lipopolysaccharide O-polysaccharide-dependent manner via the TLR4-TRAM-TRIF-IRF3-IFNAR1 pathway. Absence of SARM1 reduces the intracellular survival of K. pneumoniae in macrophages, whereas sarm1-deficient mice control the infection. Altogether, our results illustrate an anti-immunology strategy deployed by a human pathogen. SARM1 inhibition will show a beneficial effect to treat Klebsiella infections.
科研通智能强力驱动
Strongly Powered by AbleSci AI